Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients.
Advances in experimental medicine and biology
Biomarkers; Breast cancer; CTCs; DTCs; Liquid biopsy; MRD; Melanoma; Micrometastases; cfDNA; cfmiR
Melanoma and breast cancer (BC) patients face a high risk of recurrence and disease progression after curative surgery and/or therapeutic treatment. Monitoring for minimal residual disease (MRD) during a disease-free follow-up period would greatly improve patient outcomes through earlier detection of relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clinical applications of MRD monitoring in melanoma and BC patients and highlight the current approaches for detecting MRD in these solid tumors.
Women & Children
Lin, Selena Y; Orozco, Javier I J; and Hoon, Dave S B, "Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients." (2018). Articles, Abstracts, and Reports. 947.